MUNDIPHARMA INTERNATIONAL CORPORATION LTD has a total of 20 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2014. It filed its patents most often in United Kingdom, Australia and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are KNOPP BIOSCIENCES LLC, OPTIKIRA LLC and CORTEX PHARMA INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 6 | |
#2 | Australia | 4 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Brazil | 1 | |
#6 | Israel | 1 | |
#7 | Mexico | 1 | |
#8 | El Salvador | 1 | |
#9 | Ukraine | 1 | |
#10 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Wang Ling | 7 |
#2 | Wu Jay Jie-Qiang | 6 |
#3 | Ling Wang | 3 |
#4 | Mehrling Thomas Jorg | 2 |
#5 | Lopez Francisco Ibanez | 2 |
#6 | Hilgier Katarina | 2 |
#7 | Jay Jie-Qiang Wu | 2 |
#8 | Jay Jie Qiang Wu | 1 |
#9 | Gullans Steven R | 1 |
#10 | Utku Nalan | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020128912A1 | Compounds for treating lymphoma or a t-cell malignant disease | |
GB201909594D0 | Etoposide toniribate formulation | |
GB201909584D0 | Etoposide toniribate formulation | |
GB201908434D0 | Compounds for treating lymphoma or a t-cell malignant disease | |
GB201908436D0 | Compounds for treating multiple myeloma | |
GB201903005D0 | Compounds for treating multiple myeloma | |
GB201820643D0 | Compounds for treating multiple myeloma | |
AU2015318324A1 | Crystalline forms of tyrosine kinase inhibitors and their salts |